Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Dec 13:10:679.
doi: 10.1186/1471-2407-10-679.

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method

Roelof W F van Leeuwen  1 , Eleonora L Swart, Frits A Boom, Martin S Schuitenmaker, Jacqueline G Hugtenburg
Affiliations
Multicenter Study

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method

Roelof W F van Leeuwen et al. BMC Cancer. .

Abstract

Background: The pharmacotherapeutic treatment of patients with cancer is generally associated with multiple side-effects. Drug interactions and duplicate prescriptions between anti-cancer drugs or interactions with medication to treat comorbidity can reinforce or intensify side-effects.The aim of the present study is to gain more insight into the prevalence of drug interactions and duplicate prescriptions among patients being treated in the outpatient day care departments for oncology and hematological illnesses. For the first time the prevalence of drug interactions with OTC-drugs in cancer patients will be studied. Possible risk factors for the occurrence of these drug-related problems will also be studied.

Methods/design: A multicenter cross-sectional observational study of the epidemiology of drug interactions and duplicate prescriptions is performed among all oncology and hemato-oncology patients treated with systemic anti-cancer drugs at the oncology and hematology outpatient day care department of the VU University medical center and the Zaans Medical Center.

Discussion: In this article the prevalence of potential drug interactions in outpatient day-care patients treated with anti-cancer agents is studied using a novel more extensive screening method. If this study shows a high prevalence of drug interactions clinical pharmacists and oncologists must collaborate to develop a pharmaceutical screening programme, including an automated electronic warning system, to support drug prescribing for ambulatory cancer patient. This programme could minimize the occurrence of drug related problems such as drug interactions and duplicate prescriptions, thereby increasing quality of life.

Trial registration: This study is registered, number NTR2238.

PubMed Disclaimer

References

    1. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38(11):504–13. - PubMed
    1. Riechelmann RP, Tannock IF, Wang L, Saad ED, Nathan AT, Kryzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600. doi: 10.1093/jnci/djk130. - DOI - PubMed
    1. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5:489–96. doi: 10.1016/S1470-2045(04)01528-1. - DOI - PubMed
    1. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of thirdgeneration aromatase inhibitors. Semin Oncol. 2003;30(Suppl 14):23–32. doi: 10.1016/S0093-7754(03)00305-1. - DOI - PubMed
    1. Cockshott ID. Bicalutamide:clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43:855–78. doi: 10.2165/00003088-200443130-00003. - DOI - PubMed

Publication types

MeSH terms

Substances